linjc16/ctgov huggingface dataset:
Limbal Astigmatic Keratotomy to Correct High Degrees of Astigmatism After Phacoemulsification

Study Overview
=================
Brief Summary
-----------------
Compare manually performed Astigmatic Keratotomy to femtosecond laser astigmatic keratotomy to manage corneal astigmatism more than three diopters after phacoemulsification.

Detailed Description
-----------------
create circumferential corneal incisions, following the limbal curvature, at 1-1.5 mm anterior to the limbus, manually and by using femtosecond laser to correct corneal astigmatism more than three diopters after phacoemulsification.

Official Title
-----------------
Comparison Between Manual Limbal Astigmatic Keratotomy and Femtosecond Laser Limbal Astigmatic Keratotomy to Correct Astigmatism More Than Three Diopters After Phacoemulsification

Conditions
-----------------
Astigmatism

Intervention / Treatment
-----------------
* Procedure: manual astigmatic keratotomy
* Procedure: femtosecond laser astigmatic keratotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Possibility to have informed consent and attendance of all study visits. Patients who have undergone conventional phacoemulsification at least one month ago. Clear cornea. Astigmatism more than 0.5 diopters. Exclusion Criteria: Corneal opacity. History of corneal surgery. Thin cornea. Astigmatism equal to or less than 0.5 diopters.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: manual Astigmatic Keratotomy<br>manual limbal Astigmatic Keratotomy using a diamond knife group | Procedure: manual astigmatic keratotomy<br>* manual astigmatic keratotomy using a diamond knife<br>|
| Experimental: femtosecond laser Astigmatic Keratotomy<br>Femtosecond laser-guided astigmatic keratotomy group | Procedure: femtosecond laser astigmatic keratotomy<br>* astigmatic keratotomy using femtosecond lase<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| astigmatism (Keratometric reading) | diopters of the astigmatism after the procedure measured by Pentacam | three month |
Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Study Overview
=================
Brief Summary
-----------------
The retrospective study investigates the part of responsibility of neuromuscular disorders associated with chronic hemiparesis in walking impairment.

Detailed Description
-----------------
After injury to the central nervous system, walking disorders are associated with complex neuromuscular mechanisms that alter the direction and intensity of the descending control, reflex reactions to kinematic changes and the mechanical components of soft tissues. The dissociated analysis of these mechanisms and their interactions during multi-segmental movements and especially during walking is poorly described. However, a quantified assessment of the responsibility of each of the neuromuscular mechanisms in the functional disorder would guide the choice of treatments. 3D gait laboratories provide kinematic data from synchronized walking to surface electromyograms as part of additional assessments to assist in the follow-up of patients with chronic hemiparesis. Retrospective analysis of these data would help to better characterize muscular activation disorders and passive resistance to movement during walking in this population.

Official Title
-----------------
Neuromechanical Characterization of Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Conditions
-----------------
Stroke, Walking, Difficulty, Spasticity/Paresis

Intervention / Treatment
-----------------
* Diagnostic Test: Gait analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Person who performed tridimensional gait analysis in laboratory Person who had a stroke at least 6 months before the gait analysis Exclusion Criteria: Any other neurological pathology or gait disorders Botulinum toxin injection in the last 3 months before the gait analysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Gait analysis|3D gait analysis with electromyographic measurements|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coefficient of antagonist activation | The coefficient of antagonist activation of gastrocnemius medialis and soleus was calculated from EMG data by the ratio between the root mean square amplitude during antagonist effort and maximal agonist effort for the same muscle. | 1 year |
Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
Patients with renal cell carcinoma who were admitted to the First Affiliated Hospital of Sun Yat-sen University from February 1, 2021, to February 1, 2022, and met the following inclusion and exclusion criteria were collected. Clinical factors influencing the prognosis of enrolled patients were retrospectively analyzed, and a predictive system was established based on this. (Inclusion criteria: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center. Exclusion criteria:a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up.)

Official Title
-----------------
Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell

Conditions
-----------------
Carcinoma, Renal Cell

Intervention / Treatment
-----------------
* Other: We do not have any interventions. This study is based on obseravation.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center Exclusion Criteria: a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with tumor progression or recurrence<br>Patients enrolled in our retrospective study with tumor progression or recurrence | Other: We do not have any interventions. This study is based on obseravation.<br>* observational retrospective study without any interventions<br>|
| Patients without tumor progression or recurrence<br>Patients enrolled in our retrospective study without tumor progression or recurrence | Other: We do not have any interventions. This study is based on obseravation.<br>* observational retrospective study without any interventions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor progression | medical imaging examinations showed tumor progression | 12 months |
Assessment of Geriatric Evaluations Impact on New AML Guidance

Study Overview
=================
Brief Summary
-----------------
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Official Title
-----------------
AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

Conditions
-----------------
AML, Adult

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy New diagnosis being considered for new line of treatment Age ≥ 50 years. Performance status 0,1, and 2 Exclusion Criteria: Inability to understand or unable to sign a written informed consent Unable to fill out questionnaires on their own and/or do not have someone to help complete them

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate physiologic age using baseline measures of physical function, depression, cognition, frailty, and PROs in newly diagnosed AML patients receiving intensive and non-intensive treatment in relation to overall survival at 1 year. | Short physical performance battery (SPPB), geriatric depression scale (GDS), mini-COG, patient reported outcomes of physical function, fatigue, depression, cognition, anxiety | At baseline, 14 days after treatment, 1 month after treatment | 
| Evaluate baseline measures of physiologic age in relation to short term mortality |  | At 30 days and 60 days | 
| Evaluate baseline measures of physiologic age in relation to grade 3, 4, and 5 toxicities from treatment |  | At baseline, 14 days after treatment, 1 month after treatment | 
| Evaluate baseline measures of physiologic age in relation to complete remission |  | At baseline, 14 days after treatment, 1 month after treatment | 
| Compare baseline measurements to serial measurements to understand how physical function changes over time with treatment |  | At baseline, 14 days after treatment, 1 month after treatment | 
| Evaluate albumin as a biomarker predictor of clinical outcomes of short term mortality, 1 year OS and toxicity |  | At 30 days and 60 days | 
| Create a predictive pre-treatment screening tool |  | At baseline, 14 days after treatment, 1 month after treatment |
Comparison of Demographic Data Mentioned by the Patients or Measured by a Physician

Study Overview
=================
Brief Summary
-----------------
OSA (Obstructive Sleep Apnea) represents a major risk of postoperative complications. Predictive scores have been developed as the STOP-Bang score and the DES-OSA score. These scores take into account morphological parameters such as weight, height, and neck circumference. These data can be contained from the patients (self-reported) or by the measurements performed by a physician. The aim of this study is to compare the accuracy of both measurements (self-reported by the patient or measured by the physicians).

Official Title
-----------------
Comparison of Demographic Data Mentioned by the Patients or Measured by a Physician

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Other: Self-reported
* Other: Measured


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients scheduled for elective surgery on a one-day hospital Exclusion Criteria: Patient refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>All patients included in this study. Investigators will record both self-reported and measured height, weight, and neck circumference in all of these patients. | Other: Self-reported<br>* Self-reported height, weight, and neck circumference<br>Other: Measured<br>* Height, weight, and neck circumference measured by the investigator.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of self-reported height measurements | The aim of this study is to determine the accuracy of the self-reported height (compared to height measured by the physician). | One month | 
| Accuracy of self-reported weight measurements | The aim of this study is to determine the accuracy of the self-reported weight (compared to height measured by the physician). | One month | 
| Accuracy of self-reported neck circumference measurements | The aim of this study is to determine the accuracy of the self-reported neck circumference (compared to height measured by the physician). | One month |
Management of Symptomatic Uterine Fibroids in Pregnancy by Laparotomic Myomectomy: a Prospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
The frequency of women presenting with a combination of uterine fibroids and pregnancy is in-creasing nowadays. Uterine fibroids in pregnancy are an unfavorable condition in themselves and being reactive to hormonal stimuli, tending to grow, can generate symptoms of different lev-els of severity. Obstetrics and gynecologists are increasingly faced with the problem of clarifying the management tactics of pregnant patients with symptomatic fibroids, who may see their preg-nancy put at risk by these masses.

Official Title
-----------------
Management of Symptomatic Uterine Fibroids in Pregnancy by Laparotomic Myomectomy: a Prospective Cohort Study

Conditions
-----------------
Uterine Fibroid, Pregnancy Related

Intervention / Treatment
-----------------
* Procedure: Laparotomic myomectomy during pregnancy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The large and giant size of UFs, which prevent the proper continuation of pregnancy and/or occupy the entire small and large pelvis, as well as invade and/or occupy the abdominal cavity. Circulatory disorders, evidenced by necrosis of the UFs. Atypical localization of UFs (cervical, isthmic, intraligamentary, etc.), which caused pelvic organ dysfunction (dysuric phenomena, tenesmus, impediment to the act of defecation, pelvic pain). Exclusion Criteria: Refusal of LPTM by the patient. Absence of urgent indication for LPTM during pregnancy.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Laparotomic myomectomy during pregnancy|Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| continuation of pregnancy | Pregnancy continuation after surgery. | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal outcome | Assessed by APGAR 1 and 5 min, birth weight, and fetal conformation. | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Uterine fibroids, Pregnancy, myomectomy, fetal outcomes
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Study Overview
=================
Brief Summary
-----------------
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED

Detailed Description
-----------------
Randomized, double-masked, study to evaluate the efficacy and safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the symptoms of dry eye disease (DED). The subjects will be followed for approximately two months.

Official Title
-----------------
A Randomized, Double-masked, Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Conditions
-----------------
Dry Eye Syndromes, Eye Diseases

Intervention / Treatment
-----------------
* Drug: OTX-DED
* Drug: Controlled Insertion
* Drug: Collagen Punctal Plug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: VAS eye dryness severity score ≥ 35 and ≤ 90 at screening. Investigator assessment of bulbar conjunctival hyperemia grade ≥ 2 (CCLRU; 0 - 4 scale). Unanesthetized Schirmer of > 0 and ≤ 10 mm. Must not have used Artificial Tears during the Screening period. IOP in both eyes ≥ 5 mmHg and ≤21 mmHg. Exclusion Criteria: Have worn contact lenses in the 4 weeks prior to the screening visit and/or are unwilling to discontinue use of contact lenses throughout the study period. Have a history of glaucoma or ocular hypertension or have a history of intraocular pressure (IOP) < 5 mmHg or > 24 mmHg.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Parallel: Participants are assigned to one of three groups in parallel for the duration of the study
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: OTX-DED 0.3mg<br> | Drug: OTX-DED<br>* 0.3mg dexamethasone ophthalmic insert<br>|
| Experimental: Controlled Insertion utilizing Collagen Punctal Plug<br> | Drug: Controlled Insertion<br>* Collagen Punctal Plug 0.2mm (Controlled Insertion)<br>|
| Placebo Comparator: Collagen Punctal Plug (Full Insertion)<br> | Drug: Collagen Punctal Plug<br>* Collagen Punctal Plug 0.2mm (Full Insertion)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of Eye Dryness Score (visual analogue scale (VAS)) | Visual Analogue Scale (0 mm - no discomfort to 100mm - maximal (the most) discomfort) | Change from baseline (CFB) at Day 15 |
Non-Stage-Matched Intervention to Enhance High School Female Students' Readiness to Engage in Regular Physical Exercise

Study Overview
=================
Brief Summary
-----------------
A non-stage-matched intervention based on the Transtheoretical Model of Change

Detailed Description
-----------------
The proposed intervention would be non-stage-matched intervention based on the Transtheoretical Model of Change. The study sample would include high school female students (72 for the study group and 72 for the control group). The study participants will be randomly allocated and assigned into each of the study and control groups. Participants will go through pretest, intervention, posttest 1, and posttest 2. There will be a 12-2eeks interval between the intervention and each of posttest 1 and posttest 2.

Official Title
-----------------
Efficacy of The Transtheoretical Model of Change in Enhancing High School Female Students' Readiness to Engage in Regular Physical Exercise: A Randomized Controlled Trial

Conditions
-----------------
Engaging in Regular Physical Exercise

Intervention / Treatment
-----------------
* Behavioral: Non-Stage-Matched Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: High school female students who do not experience any physical disability Exclusion Criteria: High school female students who experience any physical disability

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Non-Stage-Matched Intervention<br>The proposed arm would be non-Stage-matched that involves using different Processes of Change as strategies to enhance engaging in regular physical exercise. | Behavioral: Non-Stage-Matched Intervention<br>* The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stages of Change Scale for Regular Physical Exercise | Stages of Change Scale for Regular Physical Exercise | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Health Behavior, Regular Physical Exercise, High School Female Students, Transtheoretical Model of Change